Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression

Cancer Research

Volumn 65, Issue 17, 2005, Pages 7959-7967

  Agoulnik, Irina U ^a   Vaid, Ajula ^a   Bingman III, William E ^a   Erdeme, Halime ^a   Frolov, Anna ^a   Smith, Carolyn L ^a   Ayala, Gustavo ^a   Ittmann, Michael M ^a   Weigel, Nancy L ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; STEROID RECEPTOR COACTIVATOR 1;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER STAGING; CELL GROWTH; CONTROLLED STUDY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TRANSACTIVATION;

ANDROGENS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DISEASE PROGRESSION; HELA CELLS; HISTONE ACETYLTRANSFERASES; HUMANS; MALE; OLIGONUCLEOTIDES, ANTISENSE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TRANSCRIPTION FACTORS; TRANSFECTION;

EID: 24744442616     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-3541     Document Type: Article

References (33)

1. Brinkmann AO, Blok LJ, de Ruiter PE, et al. Mechanisms of androgen receptor activation and function. J Steroid Biochem Mol Biol 1999;69:307-13.
2. Alen P, Claessens F, Verhoeven G, Rombauts W, Peeters B. The androgen receptor amino-terminal domain plays a key role in p160 coactivator-stimulated gene transcription. Mol Cell Biol 1999;19:6085-97.
3. McKenna NJ, Xu J, Nawaz Z, Tsai SY, Tsai MJ, O'Malley BW. Nuclear receptor coactivators: multiple enzymes multiple complexes, multiple functions. J Steroid Biochem Mol Biol 1999;69:3-12.
4. Gregory CW, He B, Johnson RT, et al. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 2001;61:4315-9.
5. Xu J, Qiu Y, DeMayo FJ, Tsai SY, Tsai MJ, O'Malley BW. Partial hormone resistance in mice with disruption of the steroid receptor coactivator-1 (SRC-1) gene. Science 1998;279:1922-5.
6. Visakorpi T, Hyytinen E, Koivisto P, et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 1995;9:401-6.
7. Zhang L, Johnson M, Le KH, et al. Interrogating androgen receptor function in recurrent prostate cancer. Cancer Res 2003;63:4552-60.
8. Chen CD, Welsbie DS, Tran C, et ai. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004;10:33-9.
9. Tsuchiya T, Umeda M. Improvement in the efficiency of the in vitro transformation assay method using BALE/3T3 A31-1-1 cells. Carcinogenesis 1995;16:1887-94.
10. Dutertre M, Smith CL. Ligand-independent interactions of p160/steroid receptor coactivators and CREB-binding protein (CBP) with estrogen receptor-α: regulation by phosphorylation sites in the A/B region depends on other receptor domains. Mol Endocrinol 2003;17:1296-314.
11. Agoulnik IU, Krause WC, Bingman WEr, et al. Repressors of androgen and progesterone receptor action. J Biol Chem 2003;278:31136-48.
12. Taplin ME, Bubley GJ, Ko YJ, et al. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res 1999;59:2511-5.
13. Monia BP. First- and second-generation antisense oligonucleotide inhibitors targeted against human c-raf kinase. Ciba Found Symp 1997;209:107-23.
14. Cavarretta IT, Mukopadhyay R, Lonard DM, et al. Reduction of coactivator expression by antisense oligodeoxynucleotides inhibits ERα transcriptional activity and MCF-7 proliferation. Mol Endocrinol 2002;16:253-70.
15. Nazareth LV, Stenoien DL, Bingman WEr, et al. A C619Y mutation in the human androgen receptor causes inactivation and mislocalization of the receptor with concomitant sequestration of SRC-1 (steroid receptor coactivator 1). Mol Endocrinol 1999;13:2065-75.
16. James AJ, Agoulnik IU, Harris JM, et al. A novel androgen receptor mutant, A748T, exhibits hormone concentration-dependent defects in nuclear accumulation and activity despite normal hormone-binding affinity. Mol Endocrinol 2002;16:2692-705.
17. Ayala G, Wang D, Wulf G, et al. The prolyl isomerase Pin1 is a novel prognostic marker in human prostate cancer. Cancer Res 2003;63:6244-51.
18. Giri D, Ittmann M. Inactivation of the PTEN tumor suppressor gene is associated with increased angiogenesis in clinically localized prostate carcinoma. Hum Pathol 1999;30:419-24.
19. Wu HC, Hsieh JT, Gleave ME, Brown NM, Pathak S, Chung LW. Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells. Int J Cancer 1994;57:406-12.
20. Mohler JL, Gregory CW, Ford OH III, et al. The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004;10:440-8.
21. Gioeli D, Mandell JW, Petroni GR, Frierson HF Jr, Weber MJ. Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res 1999;59:279-84.
22. Debes JD, Sebo TJ, Lohse CM, Murphy LM, Haugen dAL, Tindall DJ. p300 in prostate cancer proliferation and progression. Cancer Res 2003;63:7638-40.
23. Veldscholte J, Ris-Stalpers C, Kuiper GG, et al. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 1990;173:534-40.
24. Zhang M, Magit D, Sager R. Expression of maspin in prostate cells is regulated by a positive ets element and a negative hormonal responsive element site recognized by androgen receptor. Proc Natl Acad Sci U S A 1997;94:5673-8.
25. Onate SA, Tsai SY, Tsai MJ, O'Malley BW. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 1995;270:1354-7.
26. Rowan BG, Garrison N, Weigel NL, O'Malley BW. 8-Bromo-cyclic AMP induces phosphorylation of two sites in SRC-1 that facilitate ligand-independent activation of the chicken progesterone receptor and are critical for functional cooperation between SRC-1 and CREB binding protein. Mol Cell Biol 2000;20:8720-30.
27. Sadar MD. Androgen-independent induction of prostate-specific antigen gene expression via cross-talk between the androgen receptor and protein kinase A signal transduction pathways. J Biol Chem 1999;274:7777-83.
28. Louie MC, Yang HQ, Ma AH, et al. Androgen-induced recruitment of RNA polymerase II to a nuclear receptor-p160 coactivator complex. Proc Natl Acad Sci U S A 2003;100:2226-30.
29. Yu YP, Landsittel D, Jing L, et al. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol 2004;22:2790-9.
30. Craft N, Shostak Y, Carey M, Sawyers CL. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 1999;5:280-5.
31. Gnanapragasam VJ, Leung HY, Pulimood AS, Neal DE, Robson CN. Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer. Br J Cancer 2001;85:1928-36.
32. Zegarra-Moro OL, Schmidt LJ, Huang H, Tindall DJ. Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res 2002;62:1008-13.
33. Bevan CL, Hoare S, Claessens F, Heery DM, Parker MG. The AF1 and AF2 domains of the androgen receptor interact with distinct regions of SRC1. Mol Cell Biol 1999;19:8383-92.